300233 金城医药
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)0.8515.2614.7727.8083.161
总资产报酬率 ROA (%)0.5883.4162.9764.9252.102
投入资产回报率 ROIC (%)0.7114.2343.7736.1802.558

边际利润分析
销售毛利率 (%)36.22740.13143.72746.22352.616
营业利润率 (%)2.7377.9196.38310.0916.693
息税前利润/营业总收入 (%)2.7577.9316.66110.2887.078
净利润/营业总收入 (%)1.7396.1585.4638.1553.922

收益指标分析
经营活动净收益/利润总额(%)80.398100.661108.534107.602111.833
价值变动净收益/利润总额(%)1.686-0.5880.2260.8565.785
营业外收支净额/利润总额(%)-4.5620.488-0.196-2.258-6.868

偿债能力分析
流动比率 (X)1.7471.8351.4801.3571.510
速动比率 (X)1.2601.3481.1671.0161.234
资产负债率 (%)27.69231.63036.08837.19234.800
带息债务/全部投入资本 (%)10.64814.08216.79116.82615.680
股东权益/带息债务 (%)800.639580.843471.687469.060506.267
股东权益/负债合计 (%)256.399212.483173.962166.483184.911
利息保障倍数 (X)19.847-297.68422.93024.5288.681

营运能力分析
应收账款周转天数 (天)69.20662.88560.46460.51374.018
存货周转天数 (天)123.52198.05297.67892.66581.750